Comprehensive Insights Into Basal Cell Carcinoma: Causes, Presentation, Prevention, and Modern Therapeutic Approaches.

Sophia Levit, Joshua Shoykhet, Eyal Levit

Journal: Cancer medicine 2025;14(24):e71448

PMID: 41416412

Abstract

BACKGROUND

Basal cell carcinoma (BCC) is the most common skin cancer worldwide, accounting for approximately 80% of all skin cancers. Although more prevalent among Caucasians, BCC affects individuals of all racial and ethnic groups and may present atypically in skin of color, contributing to delayed diagnosis.

AIMS

This review aims to examine the causes, clinical presentations, prevention strategies, and treatment options for BCC, with an emphasis on recent advancements and ongoing challenges in management.

MATERIALS AND METHODS

This review integrates current peer-reviewed literature with clinical insights derived from dermatologic practice, including the evaluation of representative, deidentified patient cases. Observations from clinical experience were incorporated to contextualize diagnostic approaches, management strategies, and treatment outcomes across diverse patient populations. All patient information was anonymized, and no identifiable data were included.

RESULTS

Ultraviolet (UV) radiation remains the leading cause of BCC in fair-skinned populations, whereas genetic predispositions and environmental factors play a larger role in darker-skinned individuals. Diagnostic advances, including dermoscopy and reflectance confocal microscopy, have improved detection, particularly for pigmented lesions that may mimic benign conditions. Preventative strategies include broad-spectrum physical sunscreens, protective clothing, lifestyle modifications, and supplementation such as nicotinamide, which has demonstrated potential in reducing UV-induced skin damage. Treatment options range from Mohs micrographic surgery, considered the gold standard for high-risk and cosmetically sensitive areas, to simple excision, electrodessication and curettage, radiation therapy, and advanced systemic therapies including sonic hedgehog and PD-1 inhibitors for locally advanced or metastatic disease.

DISCUSSION

Emerging diagnostic tools and expanding therapeutic modalities have enhanced the ability to tailor BCC management to individual patient risk profiles and tumor characteristics. Non-surgical and combination approaches continue to evolve, offering effective alternatives for select cases.

CONCLUSION

By integrating prevention, early diagnosis, and personalized treatment strategies, modern approaches to BCC management are improving patient outcomes and addressing the complexities of care across diverse populations, underscoring the importance of multidisciplinary and individualized management.

© 2025 The Author(s). Cancer Medicine published by John Wiley & Sons Ltd.

Address: Georgetown University, Washington, District of Columbia, USA.; CUNY Hunter College, Bachelor of Arts, New York, New York, USA.; Columbia University College of Physicians & Surgeons, New York, New York, USA.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.